Thelansis’s “Melanoma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Melanoma is an aggressive malignancy arising from melanocytes — pigment-producing cells residing predominantly in the skin but also in ocular and mucosal sites — representing the most lethal form of skin cancer due to its pronounced metastatic potential. Ultraviolet radiation-induced DNA damage, particularly cyclobutane pyrimidine dimer formation, drives mutagenesis in sporadic melanoma, while germline CDKN2A mutations underlie familial predisposition. Somatic driver mutations — BRAF V600 in approximately 50%, NRAS in 15-20%, and NF1 or KIT alterations in the remaining subtypes — activate MAPK and PI3K survival pathways. Patients present with evolving pigmented lesions characterised by the ABCDE criteria — asymmetry, border irregularity, colour variation, diameter, and evolution — with diagnosis established by excisional biopsy and histopathological assessment, including Breslow thickness, ulceration, and mitotic rate. Sentinel lymph node biopsy guides locoregional staging, while PET-CT and brain MRI are essential for metastatic evaluation. Surgical excision with appropriate margins remains the cornerstone for localised disease. Adjuvant therapy — pembrolizumab, nivolumab, or BRAF-MEK inhibitor combinations in BRAF-mutated disease — reduces recurrence risk in high-risk resected melanoma. Advanced disease management mirrors metastatic cutaneous melanoma — immune checkpoint inhibitors, BRAF-MEK targeted combinations, and lifileucel TIL therapy for refractory disease. Prognosis is stage-dependent; multidisciplinary management, dermoscopic surveillance, sun protection education, and patient-centred care are integral to optimising outcomes.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Melanoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Melanoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.